Oct. 5, 2012
/PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today announced it will be hosting a meeting for analysts and investors on
October 11, 2012
. During the meeting, independent experts in the field of diabetes will provide an overview of the unmet medical needs and review the therapeutics in development as they relate to Biodel's major programs. Biodel's senior management will review the company's pipeline in areas of ultra-rapid-acting insulin, glucagon and other aspects of the business.
, PhD, Founder, former CEO and Scientific Advisor Profil Institute for Metabolic Research will present the limitations of current meal-time insulins and what the future holds.
, MBA, BSN, RN, CDE, FAADE, President of Big Picture Health and former President of the Diabetes Health and Wellness Institute (affiliate of Baylor Health Care Systems) will discuss hypoglycemia and using glucagon in clinical practice.
, MD, PhD, Investigator at the Massachusetts General Hospital Diabetes Research Center in
and Assistant Professor of Medicine at
Harvard Medical School
will be joined by
, PhD, Associate Professor of Biomedical Engineering at
to describe the coming of age of the bionic endocrine pancreas. Biodel's senior management will review the company's product candidates being developed to address the issues described by the independent experts.
The presentations will be webcast live through the "Investors" section of the company's website beginning at
8:30 a.m. Eastern Time
. To access the webcast, please log on to Biodel's website at
approximately fifteen minutes prior to the presentation to register and download any necessary audio software. A recording will be made available on the website for 90 days following the event.
About Biodel Inc.